Our Mission

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and pancreatic cancer has some of the lowest 5-year survival rates of any cancer. Early detection can improve survival rates. When pancreatic ductal adenocarcinoma is initially diagnosed at stage IV, patients have a 2.7% 5-year survival rate. When diagnosis occurs at Stage I or IIA, this improves to 34%. However, there are currently no accurate blood tests for early detection of pancreatic cancer.

The OCTSI has partnered with the OUHC Department of Pediatrics and been awarded a grant from the National Institutes of Health to develop the Oklahoma Pediatric Clinical Trial Network. This network will be part of the IDeA States Pediatric Clinical Trials Network that is participating in the Environmental Impacts of Child Health Outcomes (ECHO) Program to effectively investigate the impacts of environmental exposures from the womb through later years in a child’s life. The Principal Investigator of this award is Dr. Paul Darden, Chief of General and Community Pediatrics at OUHC.

The Southern Plains Tribal Health Board, the Oklahoma delegation from the National Institutes of Health (NIH) Tribal Advisory Committee, and the All of Us Research Program are hosting a listening session on Tuesday, October 22, 2019 in Oklahoma City, OK.

The All of Us Research Program, part of NIH, has a simple mission: to speed up health research breakthroughs and help foster an era of precision medicine for all.

What: The goals for this listening session are to: